Trial reportJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2013
Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis.
Trial report in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Meta-analysis of the effectiveness of heparin in suppressing physiological myocardial FDG uptake in PET/CT.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Pooled it
- 18F-fluorodeoxyglucose use after cardiac transplant: A comparative study of suppression of physiological myocardial uptake.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Trial
- Determinants of diagnostic yield and scan quality of [Critical care (London, England) · 2026Article
- A framework for exclusion of alternative diagnoses in sarcoidosis.Journal of autoimmunity · 2024Review
- Effective suppression of myocardial glucose uptake using predesigned low-carbohydrate boxed meals.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Characterization of a highly effective preparation for suppression of myocardial glucose utilization.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?EJNMMI research · 2018Article
- Cardiac magnetic resonance imaging-indeterminate/negative cardiac sarcoidosis revealed byJournal of medical case reports · 2017Review
- Joint SNMMI-ASNC expert consensus document on the role ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Fluorine-18 fluorodeoxyglucose positron emission tomography for cardiac sarcoidosis-is it time to consider a new radiotracer?EJNMMI research · 2017Article
- Joint SNMMI-ASNC Expert Consensus Document on the Role ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Continuing evolution in preparation protocols forJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Challenges of cardiac inflammation imaging with F-18 FDG positron emission tomography.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis.EJNMMI research · 2016Article
- The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- Pathophysiology and clinical management of cardiac sarcoidosis.Nature reviews. Cardiology · 2015Review
- Nuclear Molecular Imaging for Vulnerable Atherosclerotic Plaques.Korean journal of radiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography preceded by extended fasting is used to demonstrate active cardiac sarcoidosis. However, physiological insulin-dependent myocardial 18F-FDG uptake often obscures 18F-FDG uptake in sarcoid lesions. We therefore aimed to completely suppress physiological myocardial 18F-FDG uptake by pharmaceutically blocking endogenous insulin secretion while elevating free fatty acids (FFAs). METHODS AND
resultsSix patients with suspected cardiac sarcoidosis were studied in a randomized cross-over design: (1) 12 hours fasting followed by 2 hours saline infusion (SALINE), and (2) 12 hours fasting followed by 2 hour infusions of somatostatin (300 μg/hour) and heparin (70 mIE/kg/minutes) (SOMA). 18F-FDG PET scans were performed post-infusion. Glucose, insulin, and FFA levels were measured and left ventricle SUV-values were recorded. During the SALINE infusion, insulin, glucose, and FFAs remained stable. By design, the SOMA infusions rapidly (<60 minutes) suppressed insulin completely, while FFA levels peaked at 1.13 ± 0.23 mM. However, SOMA infusions only suppressed cardiac 18F-FDG uptake insignificantly globally [SUVmean (g/mL): 4.0 ± 3.3 (SALINE) vs 2.4 ± 1.2 (SOMA), P = .15] and regionally.
conclusionsComplete insulin suppression combined with markedly increased circulating FFAs does not completely suppress physiological myocardial 18F-FDG uptake and thus conveys no extra diagnostic value compared with extended fasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.